Medicare Enrolled
Dr. Ajithkumar Puthillath, MD
Optician · Stockton, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Mixed engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Puthillath from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Puthillath?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Puthillath
Dr. Ajithkumar Puthillath is an optician specialist in Stockton, CA, with 17 years of NPI registration. Based on federal Medicare data, Dr. Puthillath performed 76,875 Medicare services across 2,315 unique beneficiaries.
Between the years covered by Open Payments, Dr. Puthillath received a total of $21,445 from 85 pharmaceutical and/or device companies across 468 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Puthillath is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 1% volume in CA
$21,445 industry payments
Medicare Practice Summary
Medicare Utilization ↗76,875
Medicare services
Top 1% in CA for optician
2,315
Unique beneficiaries
$26
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,522 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 23,040 | $18 | $69 |
| Pembrolizumab injection (Keytruda) | 19,200 | $42 | $165 |
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
15,300 | $0 | $16 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
4,010 | $22 | $124 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
3,452 | $0 | $19 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,000 | $1 | $31 |
| Injection, leucovorin calcium, per 50 mg | 1,171 | $3 | $34 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
891 | $99 | $383 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
741 | $1 | $31 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
703 | $109 | $420 |
| Cyclophosphamide, 100 mg | 619 | $16 | $75 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
519 | $24 | $93 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
473 | $12 | $52 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
447 | $2 | $40 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
420 | $12 | $46 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 396 | $3 | $81 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
374 | $8 | $33 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
343 | $23 | $89 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
310 | $71 | $266 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
236 | $1 | $31 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
207 | $55 | $213 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
178 | $143 | $556 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
177 | $54 | $199 |
| Piflufolastat F-18 diagnostic injection A diagnostic injection of the radioactive tracer piflufolastat F-18 used for imaging. The dose specified is 1 millicurie. |
171 | $488 | $2,257 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
170 | $8 | $26 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
141 | $1,363 | $4,953 |
| New patient office visit, complex (60-74 min) | 135 | $172 | $660 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 129 | $274 | $1,067 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
119 | $11 | $38 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
114 | $19 | $87 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
109 | $15 | $61 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
93 | $45 | $177 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 89 | $324 | $1,447 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
77 | $7 | $33 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
59 | $28 | $101 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
57 | $141 | $517 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
55 | $97 | $353 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
50 | $27 | $116 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
36 | $131 | $512 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
34 | $65 | $235 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
30 | $1 | $26 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
22.2% high complexity
73.6% medium
4.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$21,445
Total received (2018-2024)
Avg $3,064/year across 7 years
Top 8% in CA for optician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
85
Companies
468
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$7,723 (36.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,099 (33.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$3,994 (18.6%)
Other
Charitable contributions, space rental, and other categories
$2,628 (12.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,489
2023
$1,843
2022
$1,368
2021
$2,705
2020
$4,384
2019
$1,576
2018
$7,081
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$971
PFIZER INC.
$153
Incyte Corporation
$115
Lilly USA, LLC
$110
BeiGene USA, Inc.
$107
Astellas Pharma US Inc
$100
Janssen Biotech, Inc.
$88
AstraZeneca Pharmaceuticals LP
$70
E.R. Squibb & Sons, L.L.C.
$68
Celgene Corporation
$65
ABBVIE INC.
$62
SpringWorks Therapeutics, Inc.
$56
Regeneron Healthcare Solutions, Inc.
$46
Merck Sharp & Dohme LLC
$43
Coherus Biosciences Inc.
$40
GlaxoSmithKline, LLC.
$32
Rigel Pharmaceuticals, Inc.
$30
GENZYME CORPORATION
$28
Eisai Inc.
$27
Gilead Sciences, Inc.
$27
SUN PHARMACEUTICAL INDUSTRIES INC.
$27
Telix Pharmaceuticals
$27
ADC Therapeutics America, Inc.
$24
Tempus AI, Inc
$23
SERVIER PHARMACEUTICALS LLC
$23
Genmab U.S., Inc.
$20
Fennec Pharmaceuticals, Inc.
$19
TerSera Therapeutics LLC
$19
Azurity Pharmaceuticals, Inc.
$18
Exelixis Inc.
$18
Myriad Genetic Laboratories, Inc.
$17
Amgen Inc.
$14
Top 3 companies account for 49.8% of 2024 payments
All-time payments by company (2018-2024) ›
Kite Pharma, Inc.
$3,883
Puma Biotechnology, Inc.
$3,335
PFIZER INC.
$2,941
Novartis Pharmaceuticals Corporation
$1,470
NOVARTIS PHARMACEUTICALS CORPORATION
$1,242
Karyopharm Therapeutics Inc.
$806
Seagen Inc.
$520
Astellas Pharma US Inc
$495
Janssen Biotech, Inc.
$471
E.R. Squibb & Sons, L.L.C.
$413
Pharmacyclics LLC, An AbbVie Company
$366
AstraZeneca Pharmaceuticals LP
$321
Lilly USA, LLC
$296
Incyte Corporation
$275
GENZYME CORPORATION
$268
Amgen Inc.
$261
Celgene Corporation
$260
Takeda Pharmaceuticals U.S.A., Inc.
$249
Genentech USA, Inc.
$234
BeiGene USA, Inc.
$221
Heron Therapeutics, Inc.
$156
Exelixis Inc.
$155
ABBVIE INC.
$134
Gilead Sciences, Inc.
$131
Merck Sharp & Dohme Corporation
$126
Regeneron Healthcare Solutions, Inc.
$124
GlaxoSmithKline, LLC.
$106
Octapharma USA, Inc.
$98
Merck Sharp & Dohme LLC
$97
Janssen Scientific Affairs, LLC
$95
Eisai Inc.
$85
Blueprint Medicines Corporation
$83
Blue Earth Diagnostics Limited
$83
Pharmacyclics LLC, an AbbVie Company
$81
Myovant Sciences Inc.
$78
Rigel Pharmaceuticals, Inc.
$67
ARRAY BIOPHARMA INC
$64
PUMA BIOTECHNOLOGY, INC.
$57
SpringWorks Therapeutics, Inc.
$56
Boehringer Ingelheim Pharmaceuticals, Inc.
$56
Teva Pharmaceuticals USA, Inc.
$51
Clovis Oncology, Inc.
$49
Bayer HealthCare Pharmaceuticals Inc.
$48
Array BioPharma Inc.
$44
AbbVie, Inc.
$43
SERVIER PHARMACEUTICALS LLC
$41
TerSera Therapeutics LLC
$40
Coherus Biosciences Inc.
$40
Sun Pharmaceutical Industries Inc.
$35
Medtronic, Inc.
$33
Stemline Therapeutics Inc.
$33
Taiho Oncology, Inc.
$31
Foundation Medicine, Inc.
$31
Dendreon Pharmaceuticals LLC
$29
Daiichi Sankyo Inc.
$28
Agios Pharmaceuticals, Inc.
$28
Aurobindo Pharma USA, Inc.
$28
SUN PHARMACEUTICAL INDUSTRIES INC.
$27
Telix Pharmaceuticals
$27
Janssen Pharmaceuticals, Inc
$27
Mirati Therapeutics, Inc.
$26
ADC Therapeutics America, Inc.
$24
Otsuka America Pharmaceutical, Inc.
$24
Spectrum Pharmaceuticals Inc.
$23
Sumitomo Pharma America, Inc.
$23
Apellis Pharmaceuticals, Inc.
$23
Tempus AI, Inc
$23
Kyowa Kirin, Inc.
$21
Servier Pharmaceuticals LLC
$21
Genmab U.S., Inc.
$20
Forte Bio-Pharma LLC
$20
Fennec Pharmaceuticals, Inc.
$19
CTI BioPharma Corp.
$19
MorphoSys, US Inc.
$19
Azurity Pharmaceuticals, Inc.
$18
Jazz Pharmaceuticals Inc.
$17
Myriad Genetic Laboratories, Inc.
$17
Ipsen Biopharmaceuticals, Inc
$17
Helsinn Therapeutics (U.S.), Inc.
$16
AMAG Pharmaceuticals, Inc.
$14
EMD Serono, Inc.
$14
Secura Bio, Inc.
$14
Lexicon Pharmaceuticals, Inc.
$14
Seattle Genetics, Inc.
$13
Epizyme, Inc.,
$12
Top 3 companies account for 47.4% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AKYNZEO · ALIMTA · ALUNBRIG · Abraxane · Aliqopa · Avastin · Axumin · BENDEKA · BOSULIF · BRACANALYSIS CDX · BRAFTOVI · BRUKINSA · Beleodaq · Braftovi · CABOMETYX · CALQUENCE · CINVANTI · COSELA · CRESEMBA · CYRAMZA · Cabometyx · Cinvanti · DARZALEX · ELIQUIS · ELITEK · ELREXFIO · ELZONRIS · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · EVENITY · Epkinly · Erleada · FERAHEME · Fabhalta · Farydak · Folotyn · GAVRETO · GAZYVA · GILOTRIF · IBRANCE · ILLUCCIX · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Idhifa · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · NERLYNX · NINLARO · Nalocet · Nerlynx · Nplate · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · OJJAARA · OPDIVO · ORGOVYX · OSTEOCOOL RF ABLATION SYSTEM · PADCEV · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · Pedmark · Perjeta · REBLOZYL · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SARCLISA · SCEMBLIX · SPRYCEL · SUTENT · Somatuline Depot · TABRECTA · TALVEY · TALZENNA · TAZVERIK · TECENTRIQ · TIBSOVO · TUKYSA · Tavalisse · Tecentriq · Tibsovo · Trodelvy · Truxima · Udenyca · VENCLEXTA · VERZENIO · VIVIMUSTA · VOTRIENT · VYXEOS · Venclexta · Vitrakvi · Vonjo · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XARELTO · XOSPATA · XPOVIO · XT CDX · XTANDI · Xermelo · Xospata · YONSA · Yescarta · ZEJULA · ZYTIGA · Zevalin · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (36%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 8% for optician in CA.
Geographic Context
Opticians within 10 mi
84
Per 100K population
10.7
County median income
$88,531
Nearest hospital
ST JOSEPH'S MEDICAL CENTER OF STOCKTON
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Puthillath is a mixed practice specialist, with above-average Medicare volume (top 1% in CA), with mixed engagement industry engagement in the top 8% of CA peers, with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Puthillath experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Puthillath performed 23,040 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Puthillath receive payments from pharmaceutical companies?
Yes. Dr. Puthillath received a total of $21,445 from 85 companies across 468 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Puthillath's costs compare to other opticians in Stockton?
Dr. Puthillath's average Medicare payment per service is $26. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Puthillath) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Stockton
Browse opticians in Stockton ranked by procedure volume and transparency data.
Highest volume
Top Opticians in CA
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in CA
Which CA opticians receive the most from drug and device companies.
By company
Kite Pharma, Inc. Payments to Doctors
See all physicians who received payments from Kite Pharma, Inc.
By company
Puma Biotechnology, Inc. Payments to Doctors
See all physicians who received payments from Puma Biotechnology, Inc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology